Article
Author(s):
Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.
Daily Derm Times: March 31, 2025
Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
Celebrating Women’s History Month 2025 with Dermatology Times
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates
PASI and QoL: A New Approach to Treatment Goals